About a month into the lockdown, I’ve been trying to assess the mood and experiences of Atlantic Canadian startups, and it’s difficult to sum up in a few sentences.
Some companies have seen revenues vanish and are wondering if they’ll survive. Others have found sudden demand for their products. Cash-rich companies developing medical products are waiting to get into the lab again. And some IT startups are focusing on product development because there’s no point in trying to generate sales now.